• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Multiple myeloma (first line) - bortezomib and thalidomide

Bortezomib and thalidomide for the first-line treatment of multiple myeloma

Status:	History
Expected date of issue:	July 2011
Referral date:	March 2009
Wave:	18
Process:	MTA
Topic area: Cancer

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	Andrew Dillon
Technical Lead:	Carina Righetti and Sally Doss
Communications manager:	Alice Law
Project manager:	Lori Farrar
Assessment group:	Southampton Health Technology Assessment Centre (SHTAC) University of Southampton

Top

 

Provisional schedule

Closing date for invited submissions / evidence submission:	8 October 2009
1st appraisal committee meeting:	13 April 2010
2nd appraisal committee meeting:	08 July 2010
3rd appraisal committee meeting:	09 May 2011

Top

 

Consultees and commentators

Consultees Commentators (no right to submit or appeal) Manufacturers/sponsors Janssen-Cilag (bortezomib) Celgene (thalidomide)   Patient / carer Groups Leukaemia CARE Macmillan Cancer Support Myeloma UK Rarer Cancers Foundation Professional groups British Society for Haematology Royal College of Nursing Royal College of Pathologists Royal College of Physicians, Medical Oncology Joint Special Committee UK Myeloma Forum   Others Department of Health Hammersmith and Fulham PCT Welsh Assembly Government General Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety - Northern Ireland (DHSSPSNI) NHS Quality Improvement Scotland   Comparator manufacturers GlaxoSmithKline (melphalan)   Relevant research groups Leukaemia and Lymphoma Research Clinical Trials Research Unit (CTRU), University of Leeds   Assessment Group National Institute for Health Research Health Technology Assessment Programme Southampton Health Technology Assessment Centre, University of Southampton   Associated Guideline Groups National Collaborating Centre for Cancer   Associated Public Health Groups None

Top

 

Project history

Date Update 16 March 2011 Following the appeal decision, NICE have released an executable version of the economic model to Consultees and Commentators for consultation.  Following consultation comments will be discussed at the Appraisal Committee meeting on 9 May 2011.

Top

 

Key documents

Multiple myeloma (first line) - bortezomib and thalidomide: equality impact assessment 27 July 2011 Multiple myeloma (first line) - bortezomib and thalidomide: final appraisal determination (post appeal) 17 June 2011 Multiple myeloma (first line) - bortezomib and thalidomide: appeal 24 September 2010 Multiple myeloma (first line) - bortezomib and thalidomide: final appraisal determination 26 August 2010 Multiple myeloma (first line)- bortezomib and thalidomide: appraisal consultation 02 June 2010 Multiple myeloma (first line) - bortezomib and thalidomide: protocol 27 July 2009 Multiple myeloma (first line) - bortezomib and thalidomide: Institute's response to comments on the provisional matrix 30 June 2009 Multiple myeloma (first line) - bortezomib and thalidomide: final scope 30 June 2009 Multiple myeloma (first line) - bortezomib and thalidomide: Institute's response to comments on the draft scope 30 June 2009

This page was last updated: 27 July 2011